BRAF and neoplasm: Notably, we have observed PSCs in all tumor cell lines examined to date, including A375 melanoma cells carrying the BRAFV600E oncogene (where BRAF depletion disrupted PSC formation) as well as cancer cells such as HeLa that lack known RAS pathway mutations.